Sift Biosciences
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Oncology
Sift is a preclinical-stage biotechnology company using AI and high-throughput T-cell screening to develop peptide immunotherapies for cancer and autoimmune disease. Founded in 2024 as a UC Berkeley spin-out, Sift mines billions of microbial genes for peptide motifs that modulate immune responses in cancer and autoimmune disease. Early preclinical oncology studies have demonstrated over 50% improved tumor control in gastrointestinal and gynecologic cancer models. By leveraging pre-existing human immune memory rather than genetically engineering cells, Sift aims to deliver safe, effective, and durable treatments across oncology and autoimmune disease.
Company HQ City:
San Carlos
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2024
CEO
Yue Clare Lou
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}